CVS Health to swap Amgen and Lilly's bone drugs with biosimilars in commercial formularies [Seeking Alpha]
Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline” [Yahoo! Finance]
Oncology Biosimilars Research and Global Forecast Report 2025-2030: Targeted Therapies, Emerging Market Expansion, and Novel Biosimilar Formulations Drive Growth [Yahoo! Finance]
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Cantor Fitzgerald from $315.00 to $350.00. They now have a "neutral" rating on the stock.
Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $403.00 to $415.00. They now have a "buy" rating on the stock.